Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

NCT04318223 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

168

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Locally Advanced Breast Cancer

Interventions

DRUG: Palbociclib

Sponsor

Consorzio Oncotech